A highly diastereoselective series of Nicholas cyclisation reactions of N-Boc-protected propargylamines
摘要:
The reaction of N-Boc-protected propargylamine with salicylaldehyde derivatives and their subsequent Nicholas cyclisation reaction to provide a range of novel benzopyrans is reported. The cyclisation reactions proceeded with excellent levels of diastereoselectivity to afford compounds with cis-relative stereochemistry. As far as we are able to ascertain these are the first reported examples of Nicholas cyclisation reactions of propargyl alcohols that bear a terminal alkynyl N-protected amino motif. (C) 2012 Elsevier Ltd. All rights reserved.
[EN] ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS<br/>[FR] HÉTÉROCYCLES D'ARYLMÉTHYLIDÈNE COMME NOUVEAUX ANALGÉSIQUES
申请人:CHLORION PHARMA INC
公开号:WO2009097695A1
公开(公告)日:2009-08-13
The present invention relates to Arylmethylidene heterocycles, compositions comprising an Arylmethylidene heterocycle, and methods useful for treating or preventing pain comprising administering an effective amount of an Arylmethylidene heterocycle as depicted by the formula (Ia).The compounds, compositions, and methods of the invention are also useful for treating or preventing inflammation.
[EN] FUSED TRICYCLIC IMIDAZOLE DERIVATIVES AS MODULATORS OF TNF ACTIVITY<br/>[FR] DÉRIVÉS D'IMIDAZOLE TRICYCLIQUE CONDENSÉ COMME MODULATEURS DE L'ACTIVITÉ DU TNF
申请人:UCB BIOPHARMA SPRL
公开号:WO2015086526A1
公开(公告)日:2015-06-18
A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Pyrazolopyrimidine Macrocycles as Inhibitors of Human Immunodeficiency Virus Replication
申请人:BRISTOL-MYERS SQUIBB COMPANY
公开号:US20150232481A1
公开(公告)日:2015-08-20
The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for making and using these compounds in the treatment of HIV infection.
One-Pot Synthesis of 5-Amino-2,5-dihydro-1-benzoxepines: Access to Pharmacologically Active Heterocyclic Scaffolds
作者:Ewen D. D. Calder、Salaheddin A. I. Sharif、Fiona I. McGonagle、Andrew Sutherland
DOI:10.1021/acs.joc.5b00583
日期:2015.5.1
A one-pot multibond-forming process involving a thermally mediated Overman rearrangement and a ring closing metathesis reaction of allylic trichloroacetimidates bearing a 2-allyloxyaryl group has been developed for the synthesis of 5-amino-substituted 2,5-dihydro-1-benzoxepines. Chemoselective reduction and functionalization of these compounds allowed access to a range of pharmacologically active 5-amino-2
[EN] HEXAHYDROPYRAZINOBENZ- OR -PYRIDO-OXAZEPINES CARRYING AN OXYGEN-CONTAINING SUBSTITUENT AND USE THEREOF IN THE TREATMENT OF 5-HT2C-DEPENDENT DISORDERS<br/>[FR] HEXAHYDROPYRAZINOBENZ- OU -PYRIDO-OXAZÉPINES TRANSPORTANT UN SUBSTITUANT CONTENANT DE L'OXYGÈNE ET SON UTILISATION POUR LE TRAITEMENT D'AFFECTIONS CONDITIONNÉES PAR 5-HT2C
申请人:ABBVIE DEUTSCHLAND
公开号:WO2017089458A1
公开(公告)日:2017-06-01
The present invention relates to compound of formula (I) (I) wherein the variables are as defined in the claims and the description. The invention further relates to a pharmaceutical composition containing such compounds, to their use as modulators, especially agonists or partial agonists, of the 5-HT2C receptor, to their use for preparing a medicament for the prevention or treatment of conditions and disorders which respond to the modulation of 5-HT2C receptor, and to methods for preventing or treating conditions and disorders which respond to the modulation of 5-HT2C receptor.